老年人接种23价肺炎球菌多糖疫苗药物经济学研究的系统评价

发布时间：2019-03-17 17:35

【摘要】：目的:为我国卫生决策部门科学、合理地制定老年人接种23价肺炎球菌多糖疫苗(PPV-23)政策提供理论支持。方法:计算机检索相关期刊论文、万方数据库、Elsevier、Pub Med,筛选出老年人接种PPV-23的药物经济学评价的相关文献,分别从成本研究、效果指标、年龄等方面进行统计分析。结果:共纳入13篇文献,合计900 472例老年人,年龄均大于60岁。研究所在地为哥伦比亚、美国、意大利、比利时、荷兰及中国。从成本角度来看,每增加一个生存质量调查年(QALY)成本介于9 239~33 000美元之间;从效果指标来看,成本-效果比介于9 239~45 161美元/AQLY之间。除荷兰一项研究认为65岁以上老年人接种PPV-23不具有成本效益,应该再考虑外,其余研究均显示65岁以上老年人接种PPV-23有一定的成本效益。结论:老年人接种PPV-23具有一定的经济性,且多数国家已将其纳入国家免疫计划。我国现有的研究尚无法确定老年人接种PPV-23的经济性,因此有待开展更多、更高质量的相关研究加以确认。
[Abstract]:Aim: to provide theoretical support for the policy of vaccination of 23-valent pneumococcal polysaccharide vaccine (PPV-23) for the elderly in China's health policy-making department. Methods: the Chinese journal full-text database, Wanfang database and Elsevier,Pub Med, were searched for the relevant literatures on pharmacoeconomic evaluation of PPV-23 vaccination in the elderly. Age and other aspects of statistical analysis. Results: a total of 13 articles were included, of which 900,472 cases were older than 60 years old. The research sites are Colombia, the United States, Italy, Belgium, the Netherlands and China. From a cost point of view, the annual cost of (QALY) for each additional QOL survey was between $9,239 and $33,000, and the cost-effectiveness ratio was between $9,239 and $45,161 per AQLY for impact indicators. Except for a Dutch study that shows that vaccination of PPV-23 for people over 65 years old is not cost-effective and should be reconsidered, other studies have shown that vaccination of PPV-23 for people over 65 years of age is cost-effective to a certain extent. Conclusion: PPV-23 vaccination for the elderly has some economic benefits, and most countries have incorporated it into the national immunization program. The existing studies in China have not been able to determine the economy of PPV-23 vaccination for the elderly, so more and higher quality related studies should be carried out to confirm it.
【作者单位】：中国药科大学国际医药商学院;
【分类号】：R956

【相似文献】